Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for VistaGen Therapeutics, Inc. (VTGN : NSDQ)

• Company Description    VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. Number of Employees: 57

• Price / Volume Information    Yesterday's Closing Price: $0.52 Daily Weekly Monthly 20 Day Moving Average: 1,129,884 shares Shares Outstanding: 39.62 (millions) Market Capitalization: $20.43 (millions) Beta: 0.32 52 Week High: $5.14 52 Week Low: $0.43 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -18.68% -18.75% 12 Week -88.64% -88.75% Year To Date -22.09% -22.49%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 343 ALLERTON AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-577-3600 fax: 888-482-2602 markmcp@vistagen.com http://www.vistagen.com

• General Corporate Information    Officers Shawn K. Singh - Chief Executive Officer; and Director Margaret M. FitzPatrick - Chairman Cynthia L. Anderson - Chief Financial Officer and Treasurer Ann M. Cunningham - Director Joanne Curley - Director Peer Information VistaGen Therapeutics, Inc. (CORR.) VistaGen Therapeutics, Inc. (RSPI) VistaGen Therapeutics, Inc. (CGXP) VistaGen Therapeutics, Inc. (BGEN) VistaGen Therapeutics, Inc. (GTBP) VistaGen Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92840H400 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 12/01/25 Next Expected EPS Date: 06/16/26 Share - Related Items Shares Outstanding: 39.62 Most Recent Split Date: 6.00 (0.03:1) Beta: 0.32 Market Capitalization: $20.43 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.42 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.88 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/16/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.40 Price/Cash Flow: - Price / Sales: 29.27 EPS Growth vs. Year Ago Period: 2.17% vs. Previous Quarter: 16.67% Sales Growth vs. Year Ago Period: 29.49% vs. Previous Quarter: 17.44% ROE 12/31/25 - -109.72 09/30/25 - -90.65 06/30/25 - -74.06 ROA 12/31/25 - -89.62 09/30/25 - -76.25 06/30/25 - -64.10 Current Ratio 12/31/25 - 4.67 09/30/25 - 5.79 06/30/25 - 5.98 Quick Ratio 12/31/25 - 4.67 09/30/25 - 5.79 06/30/25 - 5.98 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - -8,486.84 09/30/25 - -8,631.90 06/30/25 - -8,633.59 Book Value 12/31/25 - 1.29 09/30/25 - 2.16 06/30/25 - 1.90 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©